You are about to leave the Clinical Value website now.

Cancel

Management of early-stage NSCLC with driver mutations

Prof Yi-Long Wu

Professor of Oncology, Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital. China

 

You are viewing an International Congress run by ATORG, The Hong Kong Cancer Therapy Society, and Roche and provided to international HCPs from around the world. Please note that prescribing information provided here may vary depending on local approval in each country. For purposes of Lung Cancer Forum, best efforts were undertaken bATORG, The Hong Kong Cancer Therapy Society, and Roche to ensure compliance with the applicable law and regulations, however, you should review your local prescribing information and consult directly the local affiliate of the relevant Company to address any questions.

Be the first to receive updates, event opportunities, and thought leadership insights.